Topical Therapies in Psoriasis Management: A Comprehensive Review of External Medications and Clinical Outcomes
Keywords:
Psoriasis, Topical Therapy, Corticosteroids, Vitamin D Analogues, Retinoids, Calcineurin Inhibitors, Keratolytics, PASI Score, Dermatology, External MedicationsAbstract
Background:
Psoriasis is a chronic, immune-mediated dermatological disorder characterized by erythematous, scaly plaques resulting from hyperproliferation of keratinocytes and dysregulated immune responses. It significantly affects patients’ quality of life and is associated with comorbidities such as metabolic syndrome and cardiovascular disease. Topical therapies remain the cornerstone of management, particularly in mild to moderate cases, due to their targeted action and relatively favorable safety profile (1–3).
Objective:
This review aims to comprehensively evaluate the role of topical (external) therapies in psoriasis management, focusing on their mechanisms of action, clinical efficacy, safety, and therapeutic outcomes.
Methods:
A narrative review was conducted using published literature from standard dermatology textbooks and peer-reviewed journals. Various classes of topical agents, including corticosteroids, vitamin D analogues, retinoids, calcineurin inhibitors, keratolytics, and emerging therapies, were analyzed. Clinical outcomes such as reduction in Psoriasis Area and Severity Index (PASI), improvement in lesion characteristics, and patient adherence were assessed.
Results:
Topical corticosteroids remain the first-line therapy due to their rapid anti-inflammatory and immunosuppressive effects, though long-term use is limited by adverse effects such as skin atrophy. Vitamin D analogues regulate keratinocyte proliferation and differentiation and are commonly used in combination with corticosteroids for enhanced efficacy and safety. Retinoids such as tazarotene normalize epidermal differentiation but may cause irritation. Calcineurin inhibitors provide a safer alternative for sensitive areas, while keratolytics and coal tar act as adjuncts by improving drug penetration and reducing scaling. Emerging therapies, including phosphodiesterase-4 inhibitors and nanotechnology-based formulations, show promising results in improving drug delivery and clinical outcomes. Overall, combination therapies demonstrate superior efficacy compared to monotherapy, with significant reductions in PASI scores and lesion severity (4–8).
Conclusion:
Topical therapies play a pivotal role in psoriasis management, offering effective and localized treatment with minimal systemic involvement. While conventional agents remain the mainstay, newer therapeutic approaches provide opportunities for improved efficacy and patient adherence. A personalized treatment strategy that balances efficacy, safety, and patient preferences is essential for optimal clinical outcomes.
References
1. Griffiths, C. E. M., & Barker, J. N. W. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370(9583), 263–271.
2. Parisi, R., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2013). Global epidemiology of psoriasis. Journal of Investigative Dermatology, 133(2), 377–385.
3. Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual Review of Immunology, 32, 227–255.
4. Menter, A., & Griffiths, C. E. M. (2007). Current and future management of psoriasis. The Lancet, 370, 272–284.
5. Lebwohl, M. (2003). Psoriasis. The Lancet, 361, 1197–1204.
6. Boehncke, W. H., & Schön, M. P. (2015). Psoriasis. The Lancet, 386, 983–994.
7. Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis pathogenesis. New England Journal of Medicine, 361, 496–509.
8. Gudjonsson, J. E., & Elder, J. T. (2007). Psoriasis: Epidemiology and pathogenesis. Clinics in Dermatology, 25, 535–546.
9. Nickoloff, B. J., & Nestle, F. O. (2004). Recent insights into psoriasis. Nature Medicine, 10, 1–7.
10. Di Meglio, P., Villanova, F., & Nestle, F. O. (2014). Psoriasis immune mechanisms. Immunity, 41, 219–231.
11. Feldman, S. R., Horn, E. J., & Balkrishnan, R. (2008). Psoriasis adherence issues. Journal of the American Academy of Dermatology, 59, 1009–1016.
12. Hengge, U. R., Ruzicka, T., & Schwartz, R. A. (2006). Topical corticosteroids. Journal of the American Academy of Dermatology, 54, 1–15.
13. Kragballe, K. (1990). Vitamin D analogues in psoriasis. British Journal of Dermatology, 122, 13–20.
14. Mason, A. R., Mason, J., & Cork, M. (2013). Topical treatments for psoriasis. Cochrane Database of Systematic Reviews, CD005028.
15. Ference, J. D., & Last, A. R. (2009). Choosing topical corticosteroids. American Family Physician, 79, 135–140.
16. Coondoo, A. (2014). Topical corticosteroid misuse. Indian Journal of Dermatology, 59, 451–455.
17. Schäcke, H., Döcke, W. D., & Asadullah, K. (2002). Mechanisms of corticosteroids. Pharmacology & Therapeutics, 96, 23–43.
18. van de Kerkhof, P. C. (2004). Combination therapy in psoriasis. Journal of Dermatological Treatment, 15, 75–78.
19. Holick, M. F. (2007). Vitamin D physiology. New England Journal of Medicine, 357, 266–281.
20. Lebwohl, M., Menter, A., & Weiss, J. (2004). Calcipotriene therapy. Journal of the American Academy of Dermatology, 50, 1–12.
21. Ashcroft, D. M., Li Wan Po, A., & Williams, H. C. (2000). Vitamin D analogues meta-analysis. British Journal of Dermatology, 142, 1137–1145.
22. Kragballe, K., & van de Kerkhof, P. C. (2006). Vitamin D safety. British Journal of Dermatology, 154, 115–121.
23. Weinstein, G. D. (1997). Tazarotene mechanism. Journal of the American Academy of Dermatology, 37, S18–S24.
24. Lebwohl, M. (1998). Tazarotene in psoriasis. Journal of the American Academy of Dermatology, 39, S38–S42.
25. Ortonne, J. P. (1996). Retinoid therapy. British Journal of Dermatology, 135, 13–17.
26. Thappa, D. M. (2009). Combination topical therapy. Indian Journal of Dermatology, Venereology and Leprology, 75, 549–551.
27. Bos, J. D., & Meinardi, M. M. (2000). Calcineurin inhibitors. The Lancet, 356, 985–986.
28. Lebwohl, M., & Freeman, A. K. (2004). Tacrolimus in psoriasis. Journal of the American Academy of Dermatology, 51, 723–730.
29. Ruzicka, T., Assmann, T., & Homey, B. (1999). Tacrolimus mechanism. Dermatology, 198, 199–203.
30. Ashcroft, D. M., & Dimmock, P. (2005). Calcineurin inhibitors review. British Journal of Dermatology, 152, 689–694.
31. Feldman, S. R. (2001). Keratolytics in psoriasis. Cutis, 68, 3–7.
32. Roelofzen, J. H., & Aben, K. K. (2007). Coal tar therapy. British Journal of Dermatology, 156, 130–136.
33. Menter, A., & Korman, N. J. (2009). Psoriasis guidelines. Journal of the American Academy of Dermatology, 60, 643–659.
34. van de Kerkhof, P. C. (2008). Coal tar limitations. Clinics in Dermatology, 26, 356–360.
35. Papp, K., & Cather, J. C. (2015). PDE-4 inhibitors. Journal of the American Academy of Dermatology, 73, 37–49.
36. Verma, D. D., & Fahr, A. (2004). Nanotechnology in dermatology. European Journal of Pharmaceutics and Biopharmaceutics, 58, 1–15.
37. Lebwohl, M. G. (2016). Emerging biologics. Journal of the American Academy of Dermatology, 74, 215–220.
38. Griffiths, C. E. M. (2017). Future psoriasis therapy. The Lancet, 390, 1218–1219.
39. Fredriksson, T., & Pettersson, U. (1978). PASI score development. Dermatologica, 157, 238–244.
40. Kragballe, K. (1991). Combination topical therapy. British Journal of Dermatology, 124, 42–47.
41. Zaghloul, S. S., & Goodfield, M. J. (2004). Adherence in psoriasis. British Journal of Dermatology, 150, 707–713.
42. Richards, H. L., & Fortune, D. G. (2004). Psychological factors. Clinical and Experimental Dermatology, 29, 351–356.
43. Nast, A., & Spuls, P. I. (2015). European psoriasis guidelines. Journal of the European Academy of Dermatology and Venereology, 29, 2277–2294.
44. Armstrong, A. W., & Robertson, A. D. (2013). Personalized psoriasis care. JAMA Dermatology, 149, 1180–1185.
45. Rendon, A., & Schäkel, K. (2019). Psoriasis therapy update. International Journal of Molecular Sciences, 20, 1475.
46. Boehncke, W. H. (2018). Psoriasis management challenges. British Journal of Dermatology, 178, 101–109.
